活体生物疗法产品和微生物组 CDMO 市场规模、份额、趋势分析报告：按应用、地区、细分市场预测，2025 年至 2030 年

活体生物治疗产品和微生物组 CDMO 市场的成长和趋势

根据 Grand View Research, Inc. 的新报告，全球活生物治疗产品和微生物组 CDMO 市场规模预计到 2030 年将达到 3.9749 亿美元，2025 年至 2030 年的复合年增长率为 38.5%。

近年来，该市场成长迅速，预计未来这一趋势将持续下去，因为患者和医疗保健提供者越来越了解活体生物疗法产品和基于微生物组的疗法在治疗各种疾病（包括发炎性肠道疾病肠道疾病、癌症和神经系统疾病）方面的潜在益处。

製药和生物技术公司对活体生物治疗产品和基于微生物组的药物的投资不断增长，推动了对专注于这些领域的CDMO的需求，预计这一趋势将在未来十年持续下去。随着LBPs和基于微生物组的疗法市场的扩张，企业正在寻求拥有开发和生产这些产品所需技能的CDMO。因此，全球CDMO市场持续成长，预计未来几年将大幅扩张。

随着这些治疗方法的开发日益复杂，将研发外包给CDMO正成为製药和生技公司颇具吸引力的选择。例如，2023年7月，临床阶段生物製药公司Exeliom Biosciences宣布完成2,630万美元的A轮资金筹措，以推进其治疗产品线的临床开发，其中包括EXL01的多项临床试验。 EXL01是一种新型免疫疗法药物，可望应用于感染疾病和癌症治疗。

活生物治疗产品和基于微生物组的疗法根据其用途拥有各自的细分市场，其中艰难梭菌类别目前占据市场主导地位。人们迫切需要有效的药物来解决復发性艰难梭菌感染疾病这一严重且日益严重的健康问题。例如，2023 年 10 月，Ferring Pharmaceuticals 在美国胃肠病学会 2023 年度科学会议上报告了 REBYOTA 的两次报告。它是美国FDA核准的首个单剂量基于微生物组的疗法，用于在 18 岁及以上成年人接受抗生素治疗后预防復发性感染疾病感染疾病(CDI)。由于对艰难梭菌和其他疾病的有效治疗需求不断增长，活体生物治疗产品和基于微生物组的药物市场预计将得到发展。

新冠疫情对活体生物治疗产品和微生物组合同开发与生产组织 (CDMO) 市场造成了重大衝击。疫情造成的干扰导致临床试验延迟、某些产品需求减少、供应链中断。然而，随着疫情相关限制措施的放鬆以及对医疗保健的关注度增加，预计活体生物治疗和微生物组治疗市场将在未来几年内復苏。该领域的公司需要适应新的挑战，并找到创新的解决方案，以便在后疫情时代保持成长。

活体生物治疗产品和微生物组 CDMO 市场报告重点

• 艰难梭菌感染疾病盛行率的上升和对有效治疗的需求的不断增长，正在推动活生物治疗产品和微生物组合同开发与製造市场的增长，其中艰难梭菌将在 2024 年占据最大的收入份额。
• 许多公司专注于开发和製造治疗艰难梭菌感染疾病的产品，推动了市场的扩张。
• 2024 年，北美活生物治疗产品和微生物组 CDMO 市场占据全球最大份额，为 76.84%。
• 预计亚太地区在预测期内的复合年增长率将达到44.82%。近年来，亚太地区市场经历了显着的成长和良好的发展趋势。

目录

第一章调查方法与范围

第二章执行摘要

第 3 章：活生物治疗产品和微生物组 CDMO 市场变数、趋势和范围

• 市场体系展望
  • 母市场展望
  • 相关/辅助市场展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 技术格局
• 定价模式分析
• 2024 年临床试验量分析
• 产业市场分析工具
  • 波特五力分析
  • PESTEL分析
  • COVID-19影响分析

第四章 活体生物治疗产品与微生物组 CDMO 市场：依应用估算与趋势分析

• 细分仪表板
• 活体生物治疗产品与微生物组CDMO市场：应用差异分析
• 2018 年至 2030 年活体生物治疗产品及微生物组 CDMO 市场规模及应用趋势分析
• 艰难梭菌
• 克隆氏症
• IBS
• 糖尿病
• 其他的

5. 活体生物疗法产品和微生物组 CDMO 市场：区域、估计和趋势分析

• 2024 年及 2030 年区域市场占有率分析
• 区域市场仪表板
• 2018-2030年市场规模及预测趋势分析
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 丹麦
  • 挪威
  • 瑞典
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 泰国
• 拉丁美洲
  • 巴西
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 科威特

第六章 竞争态势

• 竞争性分类
• Company Market Assessment Analysis, 2024
• 公司简介
  • Arrant Bio
  • 4D Pharma
  • Cerbios
  • Biose Industrie
  • Assembly Biosciences, Inc.
  • Wacker Chemie AG
  • Quay Pharmaceuticals
  • NIZO
  • Lonza
  • Inpac Probiotics

Live Biotherapeutic Products And Microbiome CDMO Market Growth & Trends:

The global live biotherapeutic products and microbiome CDMO market size is expected to reach USD 397.49 million by 2030, expanding at a CAGR of 38.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market has been growing quickly in recent years, and this trend is anticipated to continue. The rising understanding of the potential advantages of live biotherapeutic products and microbiome-based therapeutics in treating various diseases, including inflammatory bowel disease, cancer, and neurological disorders, among patients and healthcare providers.

The need for CDMOs specializing in these fields is being driven by the expanding investment by pharmaceutical and biotech businesses in live biotherapeutic products and microbiome-based medicines, and this trend is anticipated to continue in the next ten years. Companies are looking for CDMOs with the skills required to develop and produce these products as the market for LBPs and microbiome-based therapeutics grows. This has resulted in the growth of the global CDMO market, with significant expansion expected in the coming years.

Due to the increasing complexity of developing these therapies, outsourcing to CDMOs is becoming an attractive option for pharmaceutical and biotech companies. For instance, in July 2023, Exeliom Biosciences, a clinical-stage biopharmaceutical company, announced a USD 26.30 million Series A funding to advance the clinical development of its therapeutic pipeline, which includes several clinical trials of EXL01. EXL01 is a novel immunotherapy with applications in infectious diseases and cancer.

Applications-based market segments have been created for live biotherapeutic products and microbiome-based therapeutics, with the C. difficile category currently dominating the market. Effective medicines are desperately required to tackle the major and expanding health issue of recurrent C. difficile infection. For instance, in October 2023, Ferring Pharmaceuticals announced two presentations at the American College of Gastroenterology's 2023 Annual Scientific Meeting for REBYOTA. It is the first single-dose microbiome-based treatment approved by the U.S. FDA to prevent recurrent C. difficile Infection (CDI) in adults aged 18 & above following antibiotic treatment for recurrent CDI. The market for live biotherapeutic products and microbiome-based medicines is anticipated to develop since there is an increasing need for effective treatments for C. difficile and other illnesses.

The COVID-19 pandemic has significantly impacted the market for live biotherapeutic products and microbiome contract development and manufacturing organizations (CDMOs). The disruption caused by the pandemic has led to delays in clinical trials, decreased demand for certain products, and supply chain disruptions. However, with the easing of pandemic-related restrictions and the increasing focus on healthcare, the market for LBPs and microbiome-based therapies is expected to rebound in the coming years. Companies in this space will need to adapt to new challenges and find innovative solutions to maintain growth in a post-pandemic world.

Live Biotherapeutic Products And Microbiome CDMO Market Report Highlights:

• C.difficle held the largest revenue share in 2024 owing to the increasing prevalence of C.difficle infections and the growing demand for effective treatments are propelling the growth of the live biotherapeutic products and microbiome contract development and manufacturing market.
• Many companies focus on developing and manufacturing products for treating C.difficle infections, driving the market's expansion.
• North America live biotherapeutic products and microbiome CDMO market accounted for the largest share of 76.84% in 2024 of the global live biotherapeutic products and microbiome market.
• Asia Pacific is expected to grow at a CAGR of 44.82% during the forecast period. The market in Asia Pacific has witnessed significant growth and promising developments in recent years.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates and Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Purchased Database
  • 1.3.3. GVR's Internal Database
  • 1.3.4. Secondary Sources
  • 1.3.5. Primary Research
• 1.4. Information or Data Analysis
  • 1.4.1. Information Analysis
  • 1.4.2. Market Formulation & Data Visualization
  • 1.4.3. Data Validation & Publishing
• 1.5. Model Details
  • 1.5.1. Commodity Flow Analysis (Model 1)
  • 1.5.2. Top Down Market Estimation (Model 2)
  • 1.5.3. Value-Chain-Based Sizing & Forecasting (Model 3)
  • 1.5.4. Multivariate Analysis (Model 4)
• 1.6. List of Secondary Sources
• 1.7. List of Abbreviations
• 1.8. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Live Biotherapeutic Products And Microbiome CDMO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. High Potential of Live Biotherapeutic Products and Microbiome in Treating Chronic & Infectious Diseases
    • 3.2.1.2. Increase in Clinical Research on Live Biotherapeutic Products
    • 3.2.1.3. Increasing Demand for One-Stop-Shop CDMOs
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Compliance Issues in Outsourcing
    • 3.2.2.2. Availability of Substitutes
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Clinical Trial Volume Analysis, 2024
• 3.6. Industry Market Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Live Biotherapeutic Products and Microbiome CDMO Market: Application Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Live Biotherapeutic Products and Microbiome CDMO Market Application Movement Analysis
• 4.3. Global Live Biotherapeutic Products and Microbiome CDMO Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 4.4. C. Difficle
  • 4.4.1. C. Difficle Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Crohn's disease
  • 4.5.1. Crohn's Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. IBS
  • 4.6.1. IBS Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Diabetes
  • 4.7.1. Diabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pharmaceutical Transportation Services Market: Regional Estimates & Trend Analysis

• 5.1. Regional Market Share Analysis, 2024 & 2030
• 5.2. Regional Market Dashboard
• 5.3. Market Size & Forecasts Trend Analysis, 2018 to 2030 (USD Million)
• 5.4. North America
  • 5.4.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.4.2. U.S.
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Competitive scenario
    • 5.4.2.3. Regulatory scenario
    • 5.4.2.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Canada
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Competitive scenario
    • 5.4.3.3. Regulatory scenario
    • 5.4.3.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Mexico
    • 5.4.4.1. Key country dynamics
    • 5.4.4.2. Competitive scenario
    • 5.4.4.3. Regulatory scenario
    • 5.4.4.4. Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Europe
  • 5.5.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5.2. UK
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Competitive scenario
    • 5.5.2.3. Regulatory scenario
    • 5.5.2.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Germany
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Competitive scenario
    • 5.5.3.3. Regulatory scenario
    • 5.5.3.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.4. France
    • 5.5.4.1. Key country dynamics
    • 5.5.4.2. Competitive scenario
    • 5.5.4.3. Regulatory scenario
    • 5.5.4.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.5. Italy
    • 5.5.5.1. Key country dynamics
    • 5.5.5.2. Competitive scenario
    • 5.5.5.3. Regulatory scenario
    • 5.5.5.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.6. Spain
    • 5.5.6.1. Key country dynamics
    • 5.5.6.2. Competitive scenario
    • 5.5.6.3. Regulatory scenario
    • 5.5.6.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.7. Denmark
    • 5.5.7.1. Key country dynamics
    • 5.5.7.2. Competitive scenario
    • 5.5.7.3. Regulatory scenario
    • 5.5.7.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.8. Norway
    • 5.5.8.1. Key country dynamics
    • 5.5.8.2. Competitive scenario
    • 5.5.8.3. Regulatory scenario
    • 5.5.8.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.9. Sweden
    • 5.5.9.1. Key country dynamics
    • 5.5.9.2. Competitive scenario
    • 5.5.9.3. Regulatory scenario
    • 5.5.9.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.6. Asia Pacific
  • 5.6.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Japan
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Competitive scenario
    • 5.6.2.3. Regulatory scenario
    • 5.6.2.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.3. China
    • 5.6.3.1. Key country dynamics
    • 5.6.3.2. Competitive scenario
    • 5.6.3.3. Regulatory scenario
    • 5.6.3.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.4. India
    • 5.6.4.1. Key country dynamics
    • 5.6.4.2. Competitive scenario
    • 5.6.4.3. Regulatory scenario
    • 5.6.4.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.5. Australia
    • 5.6.5.1. Key country dynamics
    • 5.6.5.2. Competitive scenario
    • 5.6.5.3. Regulatory scenario
    • 5.6.5.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.6. South Korea
    • 5.6.6.1. Key country dynamics
    • 5.6.6.2. Competitive scenario
    • 5.6.6.3. Regulatory scenario
    • 5.6.6.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.7. Thailand
    • 5.6.7.1. Key country dynamics
    • 5.6.7.2. Competitive scenario
    • 5.6.7.3. Regulatory scenario
    • 5.6.7.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.7. Latin America
  • 5.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7.2. Brazil
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Competitive scenario
    • 5.7.2.3. Regulatory scenario
    • 5.7.2.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7.3. Argentina
    • 5.7.3.1. Key country dynamics
    • 5.7.3.2. Competitive scenario
    • 5.7.3.3. Regulatory scenario
    • 5.7.3.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.8. MEA
  • 5.8.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.8.2. South Africa
    • 5.8.2.1. Key country dynamics
    • 5.8.2.2. Competitive scenario
    • 5.8.2.3. Regulatory scenario
    • 5.8.2.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.3. Saudi Arabia
    • 5.8.3.1. Key country dynamics
    • 5.8.3.2. Competitive scenario
    • 5.8.3.3. Regulatory scenario
    • 5.8.3.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.4. UAE
    • 5.8.4.1. Key country dynamics
    • 5.8.4.2. Competitive scenario
    • 5.8.4.3. Regulatory scenario
    • 5.8.4.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.5. Kuwait
    • 5.8.5.1. Key country dynamics
    • 5.8.5.2. Competitive scenario
    • 5.8.5.3. Regulatory scenario
    • 5.8.5.4. Israel market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Competition Categorization
• 6.2. Company Market Assessment Analysis, 2024
• 6.3. Company Profiles
  • 6.3.1. Arrant Bio
    • 6.3.1.1. Company overview
    • 6.3.1.2. Financial performance
    • 6.3.1.3. Service benchmarking
    • 6.3.1.4. Strategic initiatives
  • 6.3.2. 4D Pharma
    • 6.3.2.1. Company overview
    • 6.3.2.2. Financial performance
    • 6.3.2.3. Service benchmarking
    • 6.3.2.4. Strategic initiatives
  • 6.3.3. Cerbios
    • 6.3.3.1. Company overview
    • 6.3.3.2. Financial performance
    • 6.3.3.3. Service benchmarking
    • 6.3.3.4. Strategic initiatives
  • 6.3.4. Biose Industrie
    • 6.3.4.1. Company overview
    • 6.3.4.2. Financial performance
    • 6.3.4.3. Service benchmarking
    • 6.3.4.4. Strategic initiatives
  • 6.3.5. Assembly Biosciences, Inc.
    • 6.3.5.1. Company overview
    • 6.3.5.2. Financial performance
    • 6.3.5.3. Service benchmarking
    • 6.3.5.4. Strategic initiatives
  • 6.3.6. Wacker Chemie AG
    • 6.3.6.1. Company overview
    • 6.3.6.2. Financial performance
    • 6.3.6.3. Service benchmarking
    • 6.3.6.4. Strategic initiatives
  • 6.3.7. Quay Pharmaceuticals
    • 6.3.7.1. Company overview
    • 6.3.7.2. Financial performance
    • 6.3.7.3. Service benchmarking
    • 6.3.7.4. Strategic initiatives
  • 6.3.8. NIZO
    • 6.3.8.1. Company overview
    • 6.3.8.2. Financial performance
    • 6.3.8.3. Service benchmarking
    • 6.3.8.4. Strategic initiatives
  • 6.3.9. Lonza
    • 6.3.9.1. Company overview
    • 6.3.9.2. Financial performance
    • 6.3.9.3. Service benchmarking
    • 6.3.9.4. Strategic initiatives
  • 6.3.10. Inpac Probiotics
    • 6.3.10.1. Company overview
    • 6.3.10.2. Financial performance
    • 6.3.10.3. Service benchmarking
    • 6.3.10.4. Strategic initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global live biotherapeutic products and microbiome CDMO market, by Region, 2018 - 2030 (USD Million)
• Table 4 Global live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 5 North America live biotherapeutic products and microbiome CDMO market, by country, 2018 - 2030 (USD Million)
• Table 6 North America live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 7 U.S. live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 8 Canada live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 9 Mexico live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 10 Europe live biotherapeutic products and microbiome CDMO market, by country, 2018 - 2030 (USD Million)
• Table 11 Europe live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 12 UK live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 13 Germany live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 14 France live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 15 Italy live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 16 Spain live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 17 Denmark live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 18 Sweden live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 19 Norway live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 20 Asia Pacific live biotherapeutic products and microbiome CDMO market, by country, 2018 - 2030 (USD Million)
• Table 21 Asia Pacific live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 22 Japan live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 23 China live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 24 India live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 25 Australia live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 26 South Korea live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 27 Thailand live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 28 Latin America live biotherapeutic products and microbiome CDMO market, by country, 2018 - 2030 (USD Million)
• Table 29 Latin America live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 30 Brazil live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 31 Argentina live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 32 MEA live biotherapeutic products and microbiome CDMO market, by country, 2018 - 2030 (USD Million)
• Table 33 MEA live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 34 South Africa live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 35 Saudi Arabia live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 36 UAE live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
• Table 37 Kuwait live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Live biotherapeutic products and microbiome CDMO market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Data analysis models
• Fig. 5 Market formulation and validation
• Fig. 6 Data validating & publishing
• Fig. 7 Commodity flow analysis
• Fig. 8 Market snapshot
• Fig. 9 Segment snapshot
• Fig. 10 Competitive landscape snapshot
• Fig. 11 Parent market outlook, 2024 (USD Billion)
• Fig. 12 Ancillary market outlook, 2024 (USD Billion)
• Fig. 13 Live biotherapeutic products and microbiome CDMO market dynamics
• Fig. 14 Porter's five forces analysis
• Fig. 15 Live biotherapeutic products and microbiome CDMO market: PESTEL analysis
• Fig. 16 Live biotherapeutic products and microbiome CDMO market, by application, 2024 (USD Million)
• Fig. 17 Companies with affected trials, by size
• Fig. 18 Affected trials, by study phase
• Fig. 19 Clinical trial scenario (as of January 2024)
• Fig. 20 Live biotherapeutic products and microbiome CDMO market: Application outlook and key takeaways
• Fig. 21 Live biotherapeutic products and microbiome CDMO market: Application movement analysis
• Fig. 22 C. difficile market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 Crohn's disease market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 IBS market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Regional market: Key takeaways
• Fig. 28 Regional outlook, 2024 & 2030
• Fig. 29 Regional outlook, key takeaways
• Fig. 30 North America live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Key country dynamics
• Fig. 32 U.S. live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Key country dynamics
• Fig. 34 Canada live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Europe live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Key country dynamics
• Fig. 37 UK live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Key country dynamics
• Fig. 39 Germany live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Key country dynamics
• Fig. 41 France live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Key country dynamics
• Fig. 43 Italy live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Key country dynamics
• Fig. 45 Spain live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Key country dynamics
• Fig. 47 Denmark live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Key country dynamics
• Fig. 49 Sweden live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Key country dynamics
• Fig. 51 Norway live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Asia Pacific live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Key country dynamics
• Fig. 54 China live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Key country dynamics
• Fig. 56 Japan live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Key country dynamics
• Fig. 58 India live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Key country dynamics
• Fig. 60 Australia live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Key country dynamics
• Fig. 62 Thailand live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Key country dynamics
• Fig. 64 South Korea live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Latin America live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Key country dynamics
• Fig. 67 Brazil live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Key country dynamics
• Fig. 69 Mexico live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Key country dynamics
• Fig. 71 Argentina live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 MEA live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Key country dynamics
• Fig. 74 South Africa live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Key country dynamics
• Fig. 76 Saudi Arabia live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Key country dynamics
• Fig. 78 UAE live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Key country dynamics
• Fig. 80 Kuwait live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Market participant categorization
• Fig. 82 Heat map analysis
• Fig. 83 Market participant categorization